Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Status:
Terminated
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Local study in China and Hong Kong to evaluate safety and efficacy in lapatinib +
capecitabine in women with Human epidermal growth factor receptor 2 (HER2) positive advanced
or metastatic breast cancer.